Skip to main content
. 2020 Sep 1;27(9):959–968. doi: 10.5551/jat.51151

Table 1. Clinical and demographic characteristics of the study population in relation to 3-month outcomes.

Characteristics Good outcome (n = 925) Poor outcome (n = 165) P Value
Age, y 59.32 ± 12.64 64.13 ± 12.21 0.001
Male 636 (68.8%) 102 (61.8%) 0.037
Smoking 315 (34.5%) 67 (41.1%) 0.018
Statin use history 51 (5.5%) 15 (9.1%) 0.034
NIHSS score at admission 3 (2–5) 8 (4–12) < 0.001
Hypertension 539 (58.3%) 109 (65.8%) 0.059
CHD 99 (10.8%) 29 (17.2%) 0.013
Atrial fibrillation 41 (4.5%) 19 (11.5%) 0.004
Diabetes mellitus 182 (19.7%) 43 (25.8%) 0.057
Stroke 192 (20.9%) 51 (30.1%) 0.007
Dyslipidemia 97 (10.4%) 17 (10.2%) 0.949
WBC, 109/L 7.21 (5.91–8.41) 7.61 (6.43–8.71) 0.062
Neutrophil, 109/L 4.93 (3.62–5.71) 5.21 (4.02–6.69) 0.017
Lymphocyte, 109/L 1.73 (1.41–2.14) 1.71 (1.11–1.97) 0.059
MONO, 109/L 0.51 (0.41–0.63) 0.55 (0.43–0.67) 0.027
CHO, mmol/L 4.19 (3.49–4.87) 4.15 (3.47–4.99) 0.695
TG, mmol/L 1.35 (0.95–1.84) 1.12 (0.88–1.70) 0.012
LDL-C, mmol/L 2.67 (2.10–3.24) 2.55 (1.92–3.26) 0.280
HDL-C, mmol/L 1.09 (0.93–1.29) 1.03 (0.89–1.22) 0.036
MHR 0.48 (0.33–0.60) 0.53 (0.37–0.69) 0.007

NIHSS, National Institutes of Health Stroke Scale; CHD, coronary heart disease; WBC, white blood cell, MONO, monocyte; CHO, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein and MHR, monocyte to high-density lipoprotein ratio.